enGene Therapeutics Inc. 8-K/A

What Happened

• enGene Therapeutics (ENGN) filed an amendment to its June 2026 Form 8‑K reporting that the Board approved a plan, effective June 14, 2026, to reduce the company’s workforce by approximately 50% to preserve cash and streamline operations.
• On June 16, 2026, the Compensation Committee approved performance‑based equity retention awards tied to FDA milestones for the company’s detalimogene program. Awards are structured as performance options and restricted share units that vest only if (a) the FDA accepts the company’s BLA filing for detalimogene by September 30, 2027, and (b) the FDA approves detalimogene by December 31, 2028.

Key Details

• Workforce reduction effective June 14, 2026; Compensation Committee action on awards on June 16, 2026.
• Estimated cash restructuring costs: approximately $5.7 million to $6.4 million (primarily severance, benefits, other related costs).
• Estimated non‑cash stock‑based compensation related to restructuring: approximately $4.7 million to $5.0 million (accelerated vesting of stock options).
• Retention-related costs: up to ~$1.7 million in cash retention awards and up to ~$2.8 million in non‑cash stock‑based compensation tied to the performance‑based equity awards (including ≈$1.4M recognized on BLA milestone vesting and ≈$1.4M on approval milestone vesting).
• The company expects to record the majority of these expenses in the second half of 2026.
• The filing also includes Item 5.02 (departure/election of directors or certain officers); the provided text is incomplete — review the full 8‑K for details on any officer or director changes.

Why It Matters

• The workforce reduction and restructuring charges directly affect near‑term cash burn and reported non‑cash compensation expense; investors should expect one‑time charges in 2H 2026 that will impact operating results and cash runway.
• Performance‑based retention awards tie key employee retention costs to regulatory milestones for detalimogene (BLA acceptance and FDA approval), aligning payout with development progress but adding contingent future non‑cash compensation if milestones are achieved.
• Retail investors should review the full filed 8‑K for the omitted Item 5.02 details and monitor forthcoming updates on the BLA filing, FDA communications, and any additional restructuring developments.